ArticleFrontiers in computational neuroscience2026
Metaheuristic-driven dual-layer model for classifying Alzheimer's disease stages.
Article in Frontiers in computational neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Zero-shot multimodal pain estimation via synthetic pain simulation and domain-invariant learning.Frontiers in artificial intelligence · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Accurate determination of the progression phase of Alzheimer's disease (AD) is crucial for timely clinical decision-making, improved patient management, and personalized therapeutic interventions. However, reliably distinguishing between multiple disease stages using neuroimaging data remains a challenging task. Methods: This study proposes an advanced machine learning framework for multi-stage AD classification using magnetic resonance imaging (MRI) data. The architecture follows a two-tier design. In the first stage, convolutional neural networks (CNNs) are employed to extract deep and discriminative feature representations from MRI images. In the second stage, these features are classified using ensemble learning models, specifically XGBoost and LightGBM. Metaheuristic optimization strategies are applied to further enhance model performance. The proposed framework was evaluated using a publicly available Alzheimer's disease dataset under three different experimental configurations. Results: Experimental results demonstrate that the proposed approach effectively addresses the multi-class classification problem across different AD progression stages. The optimized models achieved a maximum classification accuracy of 89.55%, indicating robust predictive performance and strong generalization capability. Discussion: To improve transparency and clinical relevance, explainable artificial intelligence (XAI) techniques were incorporated to interpret model predictions and highlight feature importance. The results provide meaningful insights into neuroimaging biomarkers associated with AD progression and support the development of more interpretable and trustworthy diagnostic systems. Overall, the proposed framework contributes to improved data-driven decision support and offers a promising direction for future Alzheimer's disease diagnosis and staging research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.